New & Notable
As the FDA targets synthetic dyes in food, will drugs be next?
The FDA and HHS plan to revoke authorization of two synthetic food dyes and urge the food sector to drop six more by 2026, hinting drug makers could soon face similar pressure.
How Trump's pharma tariffs disrupt drug supply chains
With Trump's tariffs and global retaliation looming, pharmaceutical companies face financial risk, regulatory hurdles and pressure to quickly localize drug supply chains.
How Trump’s tariffs threaten MedTech supply chains
President Trump’s proposed 10% import tariffs could disrupt U.S. MedTech supply chains, driving up costs and triggering compliance and manufacturing challenges across the industry.
Trump signals shift in drug import tariff policy
Analysts warn Trump's looming threat of pharmaceutical tariffs on drug imports could upend global pharma supply chains, drive up costs and reduce patient access to medicine.
Insights
Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
FDA clears Dexcom G7 15-Day continuous glucose monitor
Dexcom’s G7 15-Day continuous glucose monitor extends wear, improves usability and accuracy and sets a new bar for diabetes care and integration.
-
Senate Judiciary advances bipartisan drug pricing bills
The Senate Judiciary Committee advanced six bipartisan bills to the full Senate, targeting anti-competitive practices to promote competition and reduce drug prices.
-
FTC’s PBM insulin price case stalled after Trump firings
FTC’s suit over PBM insulin pricing is stalled after Trump fired two Democratic FTC commissioners, leaving the agency without enough members to forward.
-
FDA winds down GLP-1 compounding policies
With semaglutide and tirzepatide shortages resolved, the FDA has set firm deadlines ending temporary compounding policies, marking a major shift as the GLP-1 market stabilizes.
-
Orphan drugs will double their market share by 2030
By 2030, orphan drugs will double their market share to 20% of the $1.6 trillion global drug market, with a CAGR of over 10%, outperforming the 7.5% of non-orphan drugs.
-
Pharma R&D returns improve amid rising costs, competition
Deloitte reports pharma R&D returns improved to 5.9% in 2024 driven by new blockbuster drugs, rising costs, trial competition and patent expirations threaten future growth.
Features
-
Expanding orphan drug access for rare conditions
Incentives have accelerated orphan drug development, turning rare disease treatments into one of the fastest-growing and most innovative sectors in the biopharmaceutical industry.
-
Understanding spread pricing, how PBMs influence drug costs
PBM spread pricing raises drug costs by keeping the difference between insurer charges and pharmacy payouts, fueling demand for transparency and alternative pricing models.
-
Optimizing prior authorization with AI-driven efficiency
As prior authorization poses a hurdle in healthcare, AI-driven solutions are reshaping the process by reducing delays, improving efficiency and minimizing administrative burdens.
-
Exploring FDA-approved biosimilar insulin products
FDA-approved biosimilar insulin products, such as Semglee, Rezvoglar and Merilog, expand access and provide cost-effective alternatives to reference biologics.